Clinical Trial Update: Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of bortezomib, dexamethasone, and rituximab in untreated Waldenström macroglobulinemia has been completed. The update notes completion of the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: European Myeloma Network B.V. | Conditions: Waldenstroms Macroglobulinemia | Phase 2 | Status: COMPLETED